Cardiac safety, risk management, and oncology drug development

Clinical Cancer Research

Volumn 12, Issue 12, 2006, Pages 3646-3647

  Fingert, Howard J ^a   Varterasian, Mary L ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR;

CELL DAMAGE; EDITORIAL; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HUMAN; ONCOLOGY; PATIENT CARE; PRIORITY JOURNAL; QT PROLONGATION; RISK MANAGEMENT;

ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; DEPSIPEPTIDES; HEART; HUMANS; MYOCARDIUM; RISK MANAGEMENT; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33745725793     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0518     Document Type: Editorial

References (6)

1. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Can Res 2006;12:3762-73.
2. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-2.
3. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77.
4. Park YH, Park HJ, Kim B-S, et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Letters 2005; Dec 30 [Epub ahead of print]
5. Isotalo PA, Greenway DC, Donnelly JG. Metastatic alveolar rhabdomyosarcoma with increased serum creatine kinase MB and cardiac troponin T and normal cardiac troponin I (letter). Clin Chem 1999;45:1576-8.
6. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003;21:3609-15.